|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01244 3D MEDICINES
Nominal 
2.375 +0.070 (+3.037%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 210,521 | 0.647% | 356,088 | 445,647 | 634,949 | 567,392 |
| Cost of Sales | (17,768) | 9.274% | (28,179) | (36,572) | (49,091) | (42,215) |
| Gross Profit | 192,753 | -0.080% | 327,909 | 409,075 | 585,858 | 525,177 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (5,537) | 90.734% | (4,613) | (10,057) | 837 | (658,330) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (88,496) | -4.524% | (184,943) | (199,378) | (562,466) | (1,052,030) | |
| Taxation | 0 | -- | 55 | 0 | (55) | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,267 | -0.518% | 7,357 | 16,715 | 37,824 | 27,680 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (85,229) | -4.612% | (177,531) | (182,663) | (524,697) | (1,024,350) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 1,397 | -- | (337) | (1,420) | 1,241 | (4,097) |
| Depreciation & Amortisation | 6,015 | -- | 15,162 | 25,251 | 25,461 | 21,600 |
| Directors' Emoluments | -- | -- | -- | 22,103 | 288,558 | 104,379 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified (Modified Report) | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -35.000 | -2.778% | -72.000 | -75.000 | -230.000 | -2,252.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.649) | (0.860) | (0.632) | (6.129) |
| NBV per share ($) | 2.033 | -- | 2.311 | 3.040 | 3.628 | 3.689 |
| Remarks: | Real time quote last updated: 11/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -85,229 |
| %Change | -4.612% |
| EPS / (LPS) | RMB -0.350 |
| NBV Per Share (¥) | RMB 2.033 |